Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio, Inc. (CABA)
:CABA
CABA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $5.46
Previous CloseN/A
Volume846.62K
Average Volume (3M)1.49M
Market Cap
$175.61M
Enterprise Value-$75.74M
Total Cash (Recent Filing)$194.68M
Total Debt (Recent Filing)$24.89M
Price to Earnings (P/E)―
Beta4.05
Next Earnings
Nov 12, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding91,465,230
10 Day Avg. Volume1,765,097
30 Day Avg. Volume1,493,003
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.43
Enterprise Value/Revenue-46.24
Enterprise Value/Gross Profit135.73
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$12.00Price Target Upside503.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical TrialsHaving the leading number of US cell therapy clinical sites has always been a key strength of Cabaletta in accelerating patient enrollment and program progress.
Financial StabilityRecent financing closed at approximately $94M supports clinical development and extends the cash runway into the second half of 2026.
Regulatory ProgressCabaletta has reached alignment with the FDA on the pivotal trial design for rese-cel in myositis.
Bears Say
Capital NeedsThe capital needs remain a clear headwind for the company given it has few major stock moving catalysts in the near term.
Financial ChallengesDespite the recent financing, CABA's cash overhang persists, and the company will need to raise again to reach rese-cel's pivotal readouts for myositis, absent any strategic partnering.
Investor SentimentShares are down -39% YTD as investor skepticism persists on rese-cel's safety and its differentiation from other autoCART programs.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio, Inc.’s price range in the past 12 months?
Cabaletta Bio, Inc. lowest stock price was $0.98 and its highest was $5.46 in the past 12 months.
What is Cabaletta Bio, Inc.’s market cap?
Cabaletta Bio, Inc.’s market cap is $175.61M.
When is Cabaletta Bio, Inc.’s upcoming earnings report date?
Cabaletta Bio, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 55 days.
How were Cabaletta Bio, Inc.’s earnings last quarter?
Cabaletta Bio, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.08.
Is Cabaletta Bio, Inc. overvalued?
According to Wall Street analysts Cabaletta Bio, Inc.’s price is currently Undervalued.
Does Cabaletta Bio, Inc. pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
What is Cabaletta Bio, Inc.’s EPS estimate?
Cabaletta Bio, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Cabaletta Bio, Inc. have?
Cabaletta Bio, Inc. has 91,465,230 shares outstanding.
What happened to Cabaletta Bio, Inc.’s price movement after its last earnings report?
Cabaletta Bio, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cabaletta Bio, Inc.?
Currently, no hedge funds are holding shares in CABA
Cabaletta Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (503.02% Upside)
$12.00 (503.02% Upside)
Blogger Sentiment
Neutral
CABA Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.17%
12-Months-Change
Fundamentals
Return on Equity
-76.34%
Trailing 12-Months
Asset Growth
3.26%
Trailing 12-Months
Company Description
Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
CABA Stock 12 Month Forecast
Average Price Target
$12.00
▲(503.02% Upside)
Technical Analysis
Cassava Sciences
―
VistaGen Therapeutics
―
vTv Therapeutics
―
Renovaro Biosciences
―
Jasper Therapeutics
―
Ownership Overview
1.71%
Insiders
14.28% Mutual Funds
60.15% Other Institutional Investors
20.23% Public Companies and
Individual Investors